Michelle Burris, senior vice president and chief operating officer, and John Bencich, vice president and chief financial officer, are scheduled to present

Baltimore, MD

ABSTRACT TITLE: Small Modular ImmunoPharmaceutical (SMIP) Molecules Directed at the TCR Complex Block Acute Graft Versus Host Disease and Cause Minimal Cytokine Release In Vivo

ABSTRACT TITLE: Small Modular ImmunoPharmaceutical (SMIP) Molecules Directed at the TCR Complex (CD3) Block T Cell Activation and Cause Minimal Cytokine Release In Vitro

Millennium Broadway Hotel & Conference Center
145 West 44th St.
Room 404/405
New York City, NY

Barcelona, Spain

Conference web site -- http://www.ebdgroup.com/bes/program.htm

Carlsbad, CA

ABSTRACT: Beyond SMIPs™: The Development of Small Multi-Specific Immunotherapeutics

Engineering specificity for more than one therapeutic target into antibodies has been challenging. We have developed several technologies, including the Scorpion™ platform, to bind more than one target simultaneously, whether soluble ligands or cell surface receptors. These scaffolds retain the advantages of antibodies - high affinity, lack of immunogenicity, long plasma halflife - and are amenable to large-scale production and purification.

Sir Francis Drake Hotel

San Francisco

Palace Hotel, San Francisco

Resisting the Enemy Within - Keeping Score on the War Against Autoimmune Disease

http://investorforum.bio.org/opencms/bif/2009/Program/AutoImmune.html

Arthritis, lupus, gout and other debilitating inflammatory conditions are chronic autoimmune illnesses characterized by an immune system that has become misdirected. An estimated 43 million people in the United States alone develop autoimmune rheumatic conditions. By 2020, there will be 60 million diagnosed. Unfortunately, many patients do not fully respond to available treatments and those treatments that are available are known to cause further complications, such as PML. With the discovery of new molecular targets and pathways, companies are advancing new classes of medicines for autoimmune inflammatory diseases, including oral kinase inhibitors in RA and monoclonal antibodies in lupus. The current pipeline may hold the answer for millions of patients. Companies with late-stage compounds for arthritis and inflammatory diseases, key opinion leaders and advocates will provide insights on experimental new autoimmune therapies, clinical need and application and the development landscape.

Moderator:

Liana Moussatos, Ph.D, Senior Healthcare Research Analyst, Wedbush PacGrow Life Sciences

Panelists: C. Garrison Fathman, MD, Chief Division of Immunology and Rheumatology, Stanford University School of Medicine, John A. Hardin, MD, Chief Scientific Officer, Arthritis Foundation, Sandra C. Raymond, President and CEO, Lupus Foundation of America, Alan M. Solinger, MD, FACP, FACR, Vice President of Clinical Immunology, XOMA Peter A. Thompson, MD, FACP, President & CEO, Trubion Pharmaceuticals

San Diego, CA

Scorpion Molecules: Multi-Specific Binding Proteins